⌕
Spyre Therapeutics · SYRE · Nasdaq
Tenet 43 · Weak
Compare
$93.81−5.60%At closeTenet 43 · Weak
$93.81−5.56 (−5.60%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

Spyre Therapeutics (SYRE) Income Statement

Is this a real, growing, cash-generative business, or a story propped up by accounting?

Sources Company filings FilingsHow we compute thisNot investment advice

15 figures withheld by our checks. Each blank figure names its reason.

Business engineChoppy: revenue is 95% below its peak (through FY23), net margin −38238.1%. Worth your attention in FY25: Share count (+2349.6%). Visible in the receipts below.
The lines that matter · FY21–FY25
Revenue ($M)—
0.0
FY21→FY25CAGR —
Net income ($M)▲25.4%
−155.2
FY21→FY25CAGR —
Free cash flow ($M)—
—
no FY25 valueCAGR —
What the receipts whisper · what a headline number hides
Share count
+2349.6%

2.6mn → 64.4mn diluted shares since FY21. Rising share count dilutes EPS. Growth must outrun it.

What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)0.0Revenue0.0COGS0.0Gross profit−171.7R&D−47.9SG&A−209.6Op income54.4Tax & other−155.2Net income

Margin trend · direction beats level Gross Operating Net
1007550250%sector median net margin ~3%FY21FY25

The receipt · income statement · FY21–FY25 USD thousands except per-share & ratios · hover a line for its definition
USD thousands except per-share & ratios
Line itemTTM †FY25FY24FY23FY22FY21YoYCAGR 21→25
Revenue & profitability
Revenue
—0.00.0886.02,329.018,739.0——
Cost of revenue
—0.00.00.00.00.0——
Gross profit
—0.00.0—A—A18,739.0——
Research & development
259,721.0171,653.0162,790.0219,692.058,579.057,069.0▲5.4%+31.7%
Selling, general & admin
60,450.047,909.045,776.039,946.028,531.027,319.0▲4.7%+15.1%
Total operating expenses
250,171.0209,562.0208,566.0243,189.087,110.084,388.0▲0.5%+25.5%
Operating incomefeeds ROC rank
−250,171.0−209,562.0−208,566.0−242,303.0−84,781.0−65,649.0▼0.5%—
Other income, net
−13,685.054,344.0599.0−96,513.0830.0−11.0——
Pretax income
−263,856.0−155,218.0−207,967.0−338,816.0−83,951.0−65,660.0▲25.4%—
Income tax
—−15.051.0−26.0−136.0141.0——
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings
−263,856.0−155,203.0−208,018.0−338,790.0−83,815.0−65,801.0▲25.4%—
Per share
Diluted EPSbuyback-sensitive
—B—B—B—B—B—B——
Diluted shares (mn)
0.0064.420.007.340.002.63—+122.5%
Margins
Gross margin
————A—A100.0%——
Operating margin
———−27348.0%−3640.2%−350.3%——
Net margin
———−38238.1%−3598.8%−351.1%——
† TTM = trailing four quarters through 2026-09-30.A Withheld: cost of revenue is not on file, so the gross margin is not measured.B Withheld by our checks.
FY14 – FY20 · 7 more years
Unlock the full history →
5 more years of statements and CSV export are on Premium, and 7 more on Ultimate.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
Annual report filed 2026-02-19 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.
Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.